AKT1 and colonic neoplasm: For gastrointestinal cancers, BBR enhanced chemosensitivity to irinotecan via inhibition of NF-κB in colon cancer [53], and improved chemosensitivity to Cisplatin by enhancing cell apoptosis and repressing PI3K-AKt/mTOR signaling in gastric cancer [50].